LC-MS/MS analysis of proteomics samples.
The peptide samples were analyzed by LC-MS. An integrated autosampler-LC (Ultimate 3000 RSLC nanoSystem, Dionex) was used to load the peptides onto a trap column (Nano-Trap, Thermo Scientific, 2 cm, 5 µm C18) and washed for 2 min with 99% A (0.1% formic acid/H 2 O)/1% B (80% CH 3 CN, 1% formic acid). The peptides were eluted from the trap column and through a homemade nanocapillary analytical column (20 cm, 5 µm C18 packed in 360 µm o.d. x 75 µm i.d. fused silica), with an integrated electrospray tip, by reverse-phase LC (A: 0.1% formic acid; B: 80% CH 3 CN, 0.1% formic acid) with the following gradient: 0-2 min 1% B, 400 nL/min; 2-144 min to 95% B, 300 nL/min; 144.1-180 min 1% B, 400 nL/min. The eluted peptides were electrosprayed into an Orbitrap Q Exactive Plus mass spectrometer (Thermo Scientific), which was operated with a top 10 data-dependent acquisition method that consisted of one full MS1 scan (375 -1,500 m/z) followed by 10 MS2 scans of the most abundant ions recorded in the MS1 scan. Data analysis was accomplished using the IP2 (Integrated Proteomics Applications) software package, in which RawConverter was used to generate searchable MS1 and MS2 data from the .raw file followed by using the ProLuCID algorithm (publicly available at http://fields.scripps.edu/downloads.php) to search the data against a modified human protein database (UniProt human protein database with rat DGKs, angiotensin I and vasoactive intestinal peptide standards; 40,660 proteins) with the following parameters: static carbamidomethyl modification of cysteine (+57.0142 Da), differential modifications corresponding oxidized methionine (+15.9949 Da) and desthiobiotin-labeled lysine residues (+196.1212 Da), added masses of the SILAC "heavy"-labeled amino acids (+10.0083 Da for R, +8.0142 Da for K), and trypsin enzyme specificity with 2 missed cleavages. The resulting MS2 spectra-peptide sequence matches were assembled into protein identifications and filtered using DTASelect 2.0 using the --mass, --modstat, and --trypstat options with a 1% peptide FDR. ProLuCID search parameters were configured to allow for ambiguous identification of leucine/isoleucine in peptides (-a true). mzIdent files corresponding to searches were generated in IP2-Integrated Proteomics Pipeline, mzXML spectra data were extracted from the raw file using RawConverter, and uploaded into Skyline-daily 1 to determine SILAC ratios (SR) of light/heavy (vehicle/compound treated) peptides. Peptides used for analysis were assessed for quality in Skyline by the following criteria: isotope dotproduct (iDOTP) ≥ 0.8, ratio dot product (rDOTP) ≥ 0.8, and singletons (i.e. heavy-labeled peptide not detected) defined by L/H ratios > 20 were set to 20. Dot-product values are measures of similarity between the precursor peak area and expected isotope distribution (iDOTP) and between the light and heavy peak area (rDOTP) as calculated in Skyline and described previously 2, 3 . Probe-modified peptide reported in figures were manually inspected (MS1 and MS2 raw data). Figure S1 . Extracted ion chromatograms showing ATP sensitive ERK active-site peptides. Sensitivity of native ERK1 and ERK2 active-site peptides to ATP competition shows specific and activity-dependent labeling in tissue (A, B), primary cell (C), and tumor cell proteomes (D). For brain and CD4+ T cell proteomes, pretreatment with free ATP (1 mM) resulted in >90% reductions in MS1 peak intensities of ERK1 and ERK active-site peptides. For tumor (A549, H1650, and H82) and HEK293T cells, quantitation of ATP sensitivity was determined by SILAC ratios of light and heavy proteomes pretreated with DMSO or free ATP (1 mM), respectively, prior to mixing and chemoproteomic analysis. A SILAC ratio (SR) >20 denotes a singleton, which indicates near-complete blockade of active-site probe-labeling with ATP pretreatment. Chemoproteomic analysis was carried out as described in previous studies 2, 3 . Figure S2 . Identical MS2 fragmentation spectra of ERK peptides identified in mouse and bird brain proteomes. The result shows the fragmentation patterns observed in the early-eluted (RT1) and later-eluted (RT2) peaks of ERKs from mouse brain proteome are identical. Based on chemoproteomic analysis of bird brain proteomes, we demonstrated that the ERK2 active-site peptide has an elution time (LC retention) and MS2 fragmentation spectrum that match the later-eluted RT2 peak/peptide from mouse brain proteomes. These results support RT1 and RT2 as ERK1 and ERK2, respectively, in mouse brain proteomes. Near-complete blockade of probe-labeling with free ATP supports detection of MEK active sites in our chemoproteomic studies.
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